Inter partes review

VoIP-Pal Receives Favorable IPR Institution Decisions

Retrieved on: 
Tuesday, August 1, 2023
Patent, IPR, Intellectual property, PTAB, Patent Trial and Appeal Board, Verizon Communications, T-Mobile, Inter partes review, Mobile phone, Pharmaceutical industry, Amazon

The PTAB has also denied institution of T-Mobile’s corresponding IPR petition.

Key Points: 
  • The PTAB has also denied institution of T-Mobile’s corresponding IPR petition.
  • As a result of these events, all IPR petitions against the Company have now been terminated.
  • “We are very happy to be finished with all the IPR challenges to our patents,” said Emil Malak, CEO of VoIP-Pal.
  • “It is a very significant accomplishment for us to have survived 28 IPR challenges over the past seven years without losing a single claim.

RideCo Receives Favorable Pre-Trial Rulings in Patent Litigation with Via Transportation

Retrieved on: 
Wednesday, July 26, 2023
Via Transportation, Patent Trial and Appeal Board, Court, Inter partes review, LOS, Patent, Transport, Hearing, United States district court, Generic drug, Via

RideCo secures court wins on several important issues in advance of trial in its patent litigation with Via Transportation ("Via").

Key Points: 
  • RideCo secures court wins on several important issues in advance of trial in its patent litigation with Via Transportation ("Via").
  • Ruling from the bench, the Court denied each of Via's motions heard by the Court.
  • We are glad that the Court took a careful look at these motions, and we are pleased with the favorable rulings.
  • RideCo is well-positioned for trial where we will seek to stop Via's ongoing infringement through an injunction," said Prem Gururajan, CEO of RideCo.

AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing

Retrieved on: 
Monday, July 24, 2023
Biotechnology, Pharmaceutical, Health, Patent, Intellectual property, IPR, University, ABCL, PTAB, Cell, Patent Trial and Appeal Board, District court, Inter partes review, UBC, 3D printing, AbCellera

AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) has denied a rehearing request in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No.

Key Points: 
  • AbCellera (Nasdaq: ABCL) announced that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeal Board (PTAB) has denied a rehearing request in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera’s U.S. Patent No.
  • Thereafter, Berkeley Lights sought rehearing and the PTAB again rejected Berkeley Lights’ claims.
  • “The PTAB’s decision denying Berkeley Lights’ rehearing request fortifies the strength of our microfluidic cell-culture-system patent claims,” said Tryn Stimart, J.D., Chief Legal and Compliance Officer of AbCellera.
  • We look forward to the District Court resuming our patent infringement cases against Berkeley Lights.”

U.S. Federal Circuit Affirms All District Court Rulings in Patent Litigation

Retrieved on: 
Monday, July 24, 2023
1836 U.S. Patent Office fire, Patent, Drug, IPR, United States Court of Appeals for the Federal Circuit, United States District Court for the Southern District of Alabama, Inter partes review, PAH, Calendar, PTAB, Patent Trial and Appeal Board, District court, United Therapeutics, Orthostatic hypertension, Pulmonary hypertension, UTHR, Generic drug

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR

Key Points: 
  • Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR
    MORRISVILLE, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the Court of Appeals for the Federal Circuit (Federal Circuit) has affirmed all rulings by the United States District Court for the District of Delaware (District Court) in litigation filed by United Therapeutics (UTHR) under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman litigation), which alleged that Liquidia’s YUTREPIA™ (treprostinil) inhalation powder infringes U.S. Patent No.
  • 10,716,793 (‘793 Patent).
  • UTHR has appealed the PTAB’s decision to the Federal Circuit and briefing should be completed in the fourth quarter of 2023.
  • If the Federal Circuit upholds the PTAB decision, then Liquidia will seek final regulatory approval for YUTREPIA.

Knobbe Martens Secures Complete Victory for Spectrum Solutions in Covid-19 Testing PTAB Dispute

Retrieved on: 
Wednesday, May 24, 2023
Medical Devices, Health, Professional Services, Legal, Health Technology, Patent, IPR, Intellectual property, 1836 U.S. Patent Office fire, COVID-19, Disclosure, PTAB, Inter partes review, Patent Trial and Appeal Board, Congress, History of the Food and Drug Administration, Motion, Collection, Food, Spectrum, Pharmaceutical industry, Cryptocurrency, Longhorn, Brian Knobbs

A team from Knobbe Martens led by Ali Razai secured a decisive, complete and unprecedented victory for Spectrum Solutions, LLC in inter partes review (IPR) challenges of five separate patents owned by Longhorn Vaccines & Diagnostics.

Key Points: 
  • A team from Knobbe Martens led by Ali Razai secured a decisive, complete and unprecedented victory for Spectrum Solutions, LLC in inter partes review (IPR) challenges of five separate patents owned by Longhorn Vaccines & Diagnostics.
  • Nonetheless, the PTAB cancelled all 183 claims as a result of its Sanctions Order.
  • In November 2020, Longhorn filed suit against Spectrum alleging that Spectrum’s SDNA product infringed several of Longhorn’s patents.
  • Spectrum filed a Motion for Sanctions against Longhorn and requested that the Board enter judgment against Longhorn as a result of the misconduct.

Synthego Announces Invalidation of Agilent Patents in CRISPR Dispute

Retrieved on: 
Wednesday, May 17, 2023
Patent, CRISPR, Therapy, Nucleotide, Gene editing, PTAB, RNA, Research, Patent Trial and Appeal Board, Agilent Technologies, Inter partes review, Patient, Trial, Pharmaceutical industry, Vaccine

REDWOOD CITY, Calif., May 17, 2023 /PRNewswire/ -- Synthego Corp., a leading provider of genome engineering solutions, has announced a victory in its dispute with Agilent Technologies, Inc., regarding two of Agilent's patents which have been invalidated today by a ruling of the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office.

Key Points: 
  • The PTAB ruled in favor of Synthego's petitions seeking to invalidate Agilent's US Patents Nos.
  • Synthego is pleased with the PTAB's ruling, which paves the way for continued innovation in the field of CRISPR-enabled research and therapeutics.
  • By delivering cutting-edge genome engineering solutions, Synthego empowers researchers and contributes to the advancement of CRISPR genomic medicines.
  • "The ruling confirms that the invalidated Agilent patents attempted to claim well-known modifications to guide RNAs already taught by prior art.

Therapeutic Solutions International Files to Initiate Phase III Clinical Trial for Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive COVID-19 Data with JadiCell Stem Cell Therapy

Retrieved on: 
Thursday, April 20, 2023
FDA, Health, Stem Cells, Clinical Trials, Pharmaceutical, Biotechnology, Tissue, Patent, Pressure, Oxygen, COVID-19, TSOI, Lung, Capillary, Fluid, Patient, Physician, Blood, Inter partes review, IND, Ventilator-associated lung injury, Pharmaceutical industry

Therapeutic Solutions International (TSOI) announced today filing of a new Phase III clinical trial application with the FDA for use of its JadiCell adult stem cells in treatment of acute respiratory distress syndrome (ARDS).

Key Points: 
  • Therapeutic Solutions International (TSOI) announced today filing of a new Phase III clinical trial application with the FDA for use of its JadiCell adult stem cells in treatment of acute respiratory distress syndrome (ARDS).
  • This investigational drug application (IND) is based on the Company’s existing data and experiences associated with its Phase III clinical trial in the area of COVID-19 associated ARDS.
  • ARDS is a condition in which lung injury causes fluid to leak into the spaces between the capillaries and the alveoli.
  • “We have numerous physicians eager to join the new trial, including ones who have previously witnessed significant patient improvement in previous clinical uses of our cells.”

Russ August & Kabat Announces Its New Texas Office Location Headed By Former Clerk to Judge Albright

Retrieved on: 
Monday, March 20, 2023
Confidentiality, IPR, Skin, The Honourable, Marshall, RAK, Patent, Inter partes review, Film industry, Real estate, DALLAS

DALLAS, March 20, 2023 /PRNewswire-PRWeb/ -- Russ August & Kabat is pleased to announce the opening of its new Texas office space. Peter Tong will head the office.

Key Points: 
  • Russ August & Kabat is pleased to announce the opening of its new Texas office space.
  • DALLAS, March 20, 2023 /PRNewswire-PRWeb/ -- Russ August & Kabat is pleased to announce the opening of its new Texas office space.
  • "The firm is excited to expand into Texas with the opening of our Dallas office.
  • Peter Tong joined Russ August & Kabat as a partner after completing a clerkship with the Honorable Judge Alan D. Albright in the Western District of Texas.

The Patent Trial & Appeal Board of the USPTO Rules in Favor of Continuous Composites on Six IPR Petitions Filed by Markforged

Retrieved on: 
Friday, February 10, 2023
Technology, Other Manufacturing, Electronic Design Automation, Manufacturing, Patent, Markforged, Inter partes review, Andrew Downey Orrick, NYSE, Intellectual property, Patent Trial and Appeal Board, Hearing, Continuity, Invention, IPR, PTAB, Generic drug, Pharmaceutical industry, 3D printing

The Patent Trial & Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) has recently ruled in favor of Continuous Composites Inc. , an innovator in the 3D printing industry, by denying six petitions filed by Markforged (NYSE: MKFG) for Inter Partes Review (IPR) challenging the validity of claims of Continuous Composites’ foundational patents involved in the company's ongoing patent infringement lawsuit.

Key Points: 
  • The Patent Trial & Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) has recently ruled in favor of Continuous Composites Inc. , an innovator in the 3D printing industry, by denying six petitions filed by Markforged (NYSE: MKFG) for Inter Partes Review (IPR) challenging the validity of claims of Continuous Composites’ foundational patents involved in the company's ongoing patent infringement lawsuit.
  • Continuous Composites filed a lawsuit against Markforged in July of 2021, asserting infringement of five of its foundational patents.
  • IPR2022-00548, IPR2022-00652, IPR2022-00679, IPR2022-00732, IPR2022-01218, IPR2022-01220 and IPR2022-01413), requesting cancelation of Continuous Composites’ asserted patent claims in the patents.
  • In six of the cases, the PTAB ruled in favor of Continuous Composites by denying institution of the IPRs.

Robocast Announces That the USPTO Has Denied Unified Patents Inc. Petition for Inter Partes Review of '932 Patent

Retrieved on: 
Friday, February 10, 2023
Music, Internet, Online, Technology, Entertainment, Patent, McKool Smith, Unified, United States Patent and Trademark Office, Patent Trial and Appeal Board, Netflix, NPE, Petition, Intellectual property, Inter partes review, IPR, PTAB, Generic drug, Robocasting

Robocast, a pioneering playlist technology company, announced today that on January 20, 2023, the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") denied a petition for inter partes review ("IPR"), IPR2022-01125, filed by Unified Patents Inc. against Robocast Inc.'s U.S. Patent No.

Key Points: 
  • Robocast, a pioneering playlist technology company, announced today that on January 20, 2023, the Patent Trial and Appeal Board ("PTAB") of the United States Patent and Trademark Office ("USPTO") denied a petition for inter partes review ("IPR"), IPR2022-01125, filed by Unified Patents Inc. against Robocast Inc.'s U.S. Patent No.
  • Robocast Inc. ("Robocast") was represented by powerhouse patent litigation firms McKool Smith and Cantor Colburn.
  • Unified Patents Inc., the self-proclaimed "anti-troll," incorrectly characterized Robocast as a Non-Practicing Entity ("NPE") in their failed challenge to the '932 Patent.
  • Accordingly, we deny the Petition and decline to institute an inter partes review."